Liu TC - Search Results

1

Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.

Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD, Kurtz A. Liu TC, et al. Mol Ther. 2006 Dec;14(6):789-97. doi: 10.1016/j.ymthe.2006.07.011. Epub 2006 Oct 10. Mol Ther. 2006. PMID: 17045531 Free article.

2

Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.

Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Canron X, Bikfalvi A, Martuza RL, Kurtz A, Rabkin SD. Liu TC, et al. Clin Cancer Res. 2006 Nov 15;12(22):6791-9. doi: 10.1158/1078-0432.CCR-06-0263. Clin Cancer Res. 2006. PMID: 17121900

3

Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.

Liu TC, Wakimoto H, Martuza RL, Rabkin SD. Liu TC, et al. Clin Cancer Res. 2007 Oct 1;13(19):5897-902. doi: 10.1158/1078-0432.CCR-07-1013. Clin Cancer Res. 2007. PMID: 17908985

4

Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.

Liu TC, Castelo-Branco P, Rabkin SD, Martuza RL. Liu TC, et al. Mol Ther. 2008 Jun;16(6):1041-7. doi: 10.1038/mt.2008.58. Epub 2008 Apr 1. Mol Ther. 2008. PMID: 18388912 Free PMC article.

5

Hypoxia enhances the replication of oncolytic herpes simplex virus.

Aghi MK, Liu TC, Rabkin S, Martuza RL. Aghi MK, et al. Among authors: liu tc. Mol Ther. 2009 Jan;17(1):51-6. doi: 10.1038/mt.2008.232. Epub 2008 Oct 28. Mol Ther. 2009. PMID: 18957963 Free PMC article.

6

Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Wakimoto H, Kesari S, Farrell CJ, Curry WT Jr, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD. Wakimoto H, et al. Among authors: liu tc. Cancer Res. 2009 Apr 15;69(8):3472-81. doi: 10.1158/0008-5472.CAN-08-3886. Epub 2009 Apr 7. Cancer Res. 2009. PMID: 19351838 Free PMC article.

7

An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency.

Liu TC, Hallden G, Wang Y, Brooks G, Francis J, Lemoine N, Kirn D. Liu TC, et al. Mol Ther. 2004 Jun;9(6):786-803. doi: 10.1016/j.ymthe.2004.03.017. Mol Ther. 2004. PMID: 15194046 Free article.

8

Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.

Liu TC, Kirn D. Liu TC, et al. Cancer Res. 2007 Jan 15;67(2):429-32. doi: 10.1158/0008-5472.CAN-06-2871. Cancer Res. 2007. PMID: 17234747 Review.

9

Oncolytic adenoviruses for cancer gene therapy.

Liu TC, Thorne SH, Kirn DH. Liu TC, et al. Methods Mol Biol. 2008;433:243-58. doi: 10.1007/978-1-59745-237-3_15. Methods Mol Biol. 2008. PMID: 18679628

10

Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

Lun X, Chan J, Zhou H, Sun B, Kelly JJ, Stechishin OO, Bell JC, Parato K, Hu K, Vaillant D, Wang J, Liu TC, Breitbach C, Kirn D, Senger DL, Forsyth PA. Lun X, et al. Among authors: liu tc. Mol Ther. 2010 Nov;18(11):1927-36. doi: 10.1038/mt.2010.183. Epub 2010 Aug 31. Mol Ther. 2010. PMID: 20808290 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

907 results

Search Page

Filters